Article Text

other Versions

PDF
Original research
Information leaflets for patients with hepatitis C receiving treatment with triple therapy
  1. Inés Yeste-Gómez,
  2. Carmen Guadalupe Rodríguez-González,,
  3. Álvaro Giménez-Manzorro,
  4. Arantza Ais-Larisgoitia,
  5. María Sanjurjo-Saez
  1. Department of Pharmacy, Hospital General Universitario Gregorio Marañón, Madrid, Spain;
  1. Correspondence to Dr Inés Yeste-Gómez, Department of Pharmacy, Hospital General Universitario Gregorio Marañón, Calle Dr. Esquerdo 46, 28007 Madrid, Spain; mines.yeste{at}salud.madrid.org

Abstract

The NS3/4 protease inhibitors boceprevir and telaprevir in conjunction with peginterferon α and ribavirin (triple therapy) increase the rate of a sustained virological response in patients with genotype-1 chronic hepatitis C but, to achieve a successful result, good compliance is vital. As part of a pharmaceutical care programme, in the Outpatient Pharmacy we developed information leaflets to help patients understand the objectives of triple therapy, to be aware and prevent the possible side effects and to teach patients how to take the medicines.

  • Triple therapy
  • boceprevir
  • telaprevir

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.